On 25 August 2010, orphan designation (EU/3/10/769) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[126.96.36.199(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treatment of post-polycythaemia vera myelofibrosis.
The sponsorship was transferred to Baxter Innovations GmbH, Austria, in March 2015.
The sponsorship was transferred to CTI Life Sciences Ltd, United Kingdom, in November 2016 and subsequently to CTI Life Sciences Deutschland GmbH, Germany, in May 2019.
This medicine is now known as pacritinib.
Treatment of post-polycythaemia vera myelofibrosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
EU/3/10/769: Public summary of opinion on orphan designation: 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[188.8.131.52(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treat... (PDF/149.15 KB)
First published: 18/10/2010
Last updated: 13/05/2015
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: